Baxter International Inc. (BAX)
Health Care1 article
Price chart
Why is BAX moving?
BullishJul 15AbbVie (ABBV) announced a quarterly dividend of $1.73 with a yield of 2.8%, extending its streak of increases since 2013. In contrast, Baxter (BAX) eliminated its dividend, reporting a net income loss of $900 million for FY2025, which disqualifies it from income-focused portfolios. AbbVie's revenue growth from Skyrizi and Rinvoq, at 31% and 23%, respectively, has helped offset losses from Humira and raised guidance for the year. The contrast between the two companies highlights the risks and potential for investors focused on income reliability and growth.
Read the full story →Baxter International Inc. (BAX) overview
Baxter International makes hospital and renal-care medical products. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Baxter International Inc. trades on the NYSE under the ticker symbol BAX. As of the most recent market data, the stock was priced around $23.10, up 4.29% on the session, giving Baxter International Inc. a market capitalization of roughly $11.93B.
Over the past 52 weeks, BAX has traded between $15.73 and $29.35. Baxter International Inc. also pays a dividend, currently yielding around 90.00%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch BAX
As one of the larger companies in the Health Care sector, Baxter International Inc. is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch BAX for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Market Mood
Latest BAX news
AbbVie (ABBV) Reports 2.8% Yield; Baxter (BAX) Cuts Dividend
AbbVie (ABBV) announced a quarterly dividend of $1.73 with a yield of 2.8%, extending its streak of increases since 2013. In contrast, Baxter (BAX) eliminated its dividend, reporting a net income loss of $900 million for FY2025, which disqualifies it from income-focused portfolios. AbbVie's revenue growth from Skyrizi and Rinvoq, at 31% and 23%, respectively, has helped offset losses from Humira and raised guidance for the year. The contrast between the two companies highlights the risks and potential for investors focused on income reliability and growth.
Read More: AbbVie (ABBV) Reports 2.8% Yield; Baxter (BAX) Cuts DividendMore Health Care stocks
Frequently asked questions
Is Baxter International Inc. in the S&P 500?
Yes. Baxter International Inc. (BAX) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is BAX in?
Baxter International Inc. is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest BAX news?
This page collects recent Baxter International Inc. (BAX) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Baxter International Inc.'s stock price?
As of the most recent market data, Baxter International Inc. (BAX) traded at approximately $23.10. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is Baxter International Inc.'s market cap?
Baxter International Inc. has a market capitalization of roughly $11.93B, based on its most recent share price and shares outstanding.